文献速递临床试验与 GCP基础与转化研究

应激外周血单核细胞分泌组治疗糖尿病足溃疡的安全性与临床疗效:MARSYAS II随机对照II期试验方案

Safety and clinical efficacy of the secretome of stressed peripheral blood mononuclear cells in patients with diabetic foot ulcer-study protocol of the randomized, placebo-controlled, double-blind, multicenter, international phase II clinical trial MARSYAS II.
PubMed 文献 · Trials · 2021-01-06

MARSYAS II为多中心、随机、双盲、安慰剂对照、平行组、剂量探索的I/II期研究,评估APOSEC(外周血单核细胞无细胞分泌组)与水凝胶混合后局部外用治疗糖尿病足溃疡的安全性与疗效。共计划入组132例患者,按三个剂量水平或安慰剂治疗4周,随访8周。主要终点为治疗4周后创面面积缩小。

要点

  • APOSEC为无细胞分泌组制剂,局部外用每周三次、持续4周,设三个剂量与安慰剂对照。
  • 主要终点为治疗4周后创面面积缩小,随访8周评估安全性。
  • 计划入组132例糖尿病足溃疡患者,多中心随机双盲设计。

核心结论

  • 该研究方案被认为适合在I/II期临床试验中评估局部外用APOSEC治疗糖尿病足溃疡患者。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照、平行组、剂量探索的I/II期临床研究,计划入组132例患者。
  • APOSEC与水性凝胶混合后局部外用,每周三次、持续4周,设三个剂量水平或安慰剂,随后8周随访。

关键数值与推荐

  • 主要终点为治疗4周后创面面积缩小。
  • APOSEC在缺氧诱导的组织损伤中主要通过调节免疫系统和增强血管生成发挥作用,并具有抗微生物能力和神经再生能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diabetes and its sequelae such as diabetic foot ulcer are rising health hazards not only in western countries but all over the world. Effective, yet safe treatments are desperately sought for by physicians, healthcare providers, and of course patients. METHODS/DESIGN: APOSEC, a novel, innovative drug, is tested in the phase I/II study MARSYAS II, where its efficacy to promote healing of diabetic foot ulcers will be determined. To this end, the cell-free secretome of peripheral blood mononuclear cells (APOSEC) blended with a hydrogel will be applied topically three times weekly for 4 weeks. APOSEC is predominantly effective in hypoxia-induced tissue damages by modulating the immune system and enhancing angiogenesis, whereby its anti-microbial ability and neuro-regenerative capacity will exert further positive effects. In total, 132 patients will be enrolled in the multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-ranging phase I/II study and treated with APOSEC at three dose levels or placebo for 4 weeks, followed by an 8-week follow-up period to evaluate safety and efficacy of the drug. Wound area reduction after 4 weeks of treatment will serve as the primary endpoint. CONCLUSION: We consider our study protocol to be suitable to test topically administered APOSEC in patients suffering from diabetic foot ulcers in a clinical phase I/II trial. TRIAL REGISTRATION: EudraCT 2018-001653-27 . Registered on 30 July 2019. ClinicalTrials.gov NCT04277598 . Registered on 20 February 2020. TITLE: "A randomized, placebo-controlled, double-blind study to evaluate safety and dose-dependent clinical efficacy of APO-2 at three different doses in patients with diabetic foot ulcer (MARSYAS II)".

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gugerell A, Gouya-Lechner G, Hofbauer H, et al. Safety and clinical efficacy of the secretome of stressed peripheral blood mononuclear cells in patients with diabetic foot ulcer-study protocol of the randomized, placebo-controlled, double-blind, multicenter, international phase II clinical trial MARSYAS II. Trials. 2021. PMID: 33407796. doi:10.1186/s13063-020-04948-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。